Aji Bio-Pharma Expands Agreement with AstraZeneca to Include Drug Product Manufacturing

The expanded agreement will include aseptic fill/finish services at its San Diego, CA facility.

Ajinomoto Bio-Pharma Services (Aji Bio-Pharma), announced on March 30, 2021 that it has expanded its manufacturing agreement with AstraZeneca to include drug product manufacturing.

According to an Aji Bio-Pharma press release, the expanded agreement will include aseptic fill/finish services at its San Diego, CA facility, in addition to the small molecule manufacturing services already performed in Belgium.

"We are excited to expand our manufacturing agreement with AstraZeneca and to support them with additional service offerings," said Magnus Busch, global account manager, Ajinomoto Bio-Pharma Services, in the press release. "Our San Diego team is proud to join our Belgium colleagues in support of AstraZeneca. This expanded agreement builds on our commitment to be a leading, trusted, innovative partner to our clients."

Source: Aji Bio-Pharma